Preferences & Treatment Satisfaction Drivers in Rosacea Patients

Completed

• Conditions: Rosacea
• Interventions: Drug: Azelaic Acid Cream; Drug: Metronidazole gel; Drug: Metronidazole cream; Drug: Metronidazole Emulsion; Drug: Metronidazole Lotion; Drug: Brimonidine Tartrate Gel

• Registration Number: NCT02602470
• Lead Sponsor: LEO Pharma

Brief Summary

To survey patients with rosacea about their rosacea treatment preferences as well as to assess potential drivers of rosacea treatment satisfaction.

Detailed Description

Not available

Study Timeline

• Study Start: 2015-01-08
• Study First Submitted: 2015-11-10
• Study First Submitted QC: 2015-11-10
• Study First Posted: 2015-11-11
• Primary Completion: 2016-03-10
• Study Completion: 2016-03-10
• Status Verified: 2017-04
• Last Update Submitted: 2020-03-30
• Last Update Posted: 2020-04-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 206

Inclusion Criteria

• Male or female patients of at least 18 years of age at index date
• At least one prescription for a topical rosacea treatments: Azelaic Acid Gel, Azelaic Acid Cream, Metronidazole Gel, Metronidazole Cream, Metronidazole Emulsion, Metronidazole Lotion, Brimonidine Tartrate Gel
• At least one medical record with a diagnosis code for rosacea (ICD-9: 695.3)
• At least 6 months of data history prior to the index date
• Had at least one encounter at the Reliant Medical Group within 3 months prior to 01 January 2015

Exclusion Criteria

• None

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Rosacea treated patients	Brimonidine Tartrate Gel	Patients using topical rosacea treatment
Rosacea treated patients	Metronidazole gel	Patients using topical rosacea treatment
Rosacea treated patients	Metronidazole cream	Patients using topical rosacea treatment
Rosacea treated patients	Metronidazole Lotion	Patients using topical rosacea treatment
Rosacea treated patients	Azelaic Acid Cream	Patients using topical rosacea treatment
Rosacea treated patients	Metronidazole Emulsion	Patients using topical rosacea treatment

Primary Outcome Measures

Name	Time	Method
Self-reported concerns and importance of such concerns regarding their current topical rosacea treatments	Rosacea treatment in the past 4 weeks	Assessed from the Rosacea Treatment Preference Questionnaire: Rated on a scale of 0 to 10, with 0 meaning not at all important and 10 meaning extremely important

Secondary Outcome Measures

Name	Time	Method
Quality of life	Rosacea treatment in the past 4 weeks	Measured using Dermatology Life Quality Index (DLQI): The DLQI consists of 10 questions concerning symptoms and feelings, daily activities, leisure, work, and school, personal relationships and treatment
Self-reported concerns and importance (a rating scale) of such concerns that patients would consider when switching to a new topical rosacea treatment	Rosacea treatment in the past 4 weeks	Extracted from the Rosacea Treatment Preference Questionnaire
Self-reported likelihood of switching to a topical rosacea treatments	Rosacea treatment in the past 4 weeks	Assessed from the Rosacea Treatment Preference Questionnaire: Rated on a scale of 0 to 10, with 0 meaning not at all likely and 10 meaning extremely likely
Treatment satisfaction	Rosacea treatment in the past 4 weeks	Assessed by a score on the Treatment Satisfaction with Medicines Questionnaire (SATMED-Q). Scores will be standardized and expressed as a 0-100 standardized score